Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention

NCT06909565 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

6000

Enrollment

OTHER

Sponsor class

Conditions

Percutaneous Coronary Intervention
Peripheral Endovascular Intervention

Interventions

DRUG: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
DRUG: Normal Saline (Placebo)

Sponsor

Duke University

Collaborators

[object Object]
[object Object]
[object Object]